x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

16:13

S1 Ep200: Exploring the Bone Marrow...

Oncology On The Go ·

2026/02/09

In a conversation with CancerNetwork®, Manoj Bhasin, PhD, MS, spoke about findings from a study in which he and colleagues developed a single-cell atlas characterizing the dysregulation of the bone marrow immune microenvironment in newly diagnosed multiple myeloma. Findings published in Nature Cancer showed that the immune system has a broad, treatment-independent influence on outcomes in newly diagnosed multiple myeloma.Bhasin began by detailing the background and methodology of his study, in

en-us

11:07

S1 Ep199: How to Responsibly Use AI in Palliative...

Oncology On The Go ·

2026/02/02

In a conversation with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, discussed the evolving roles that artificial intelligence (AI)–based tools may play in palliative care and the management of different hematologic malignancies. He spoke in the context of a publication he authored, The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies,which was featured in the November/December 2025 issue of the journal ONCOLOGY®.Thirugnanasambandam, a fellow

en-us

22:41

S1 Ep198: Innovation, Elevation, and Empowerment...

Oncology On The Go ·

2026/01/26

Emphasizing the evidence-based nature of medicine, Nathan Goodyear, MD, explained that integrative oncology uses many of the same parameters and key clinical thresholds among patients undergoing treatment for a diagnosis of cancer that his conventional oncologist colleagues use.In this episode of Oncology on the Go, Goodyear, an integrative medicine physician at the Williams Cancer Institute, discussed key clinical efficacy and safety thresholds that integrative oncologists use for flagship

en-us

21:04

S1 Ep197: How Can Bioimpedance Spectroscopy Help...

Oncology On The Go ·

2026/01/19

In a conversation with CancerNetwork®, Kandace P. McGuire, MD, and Paschalia Mountziaris, MD, PhD, highlighted the use of L-Dex bioimpedance spectroscopy as a method for detecting lymphedema earlier in patients who undergo surgery for breast cancer. The experts discussed seamlessly integrating this novel modality into standard vitals workflows and detailed other considerations for improving long-term survivorship outcomes via proactive lymphatic care.McGuire began by breaking down why detection of

en-us

27:38

S1 Ep196: Bolstering Outcomes and Building Bridges in...

Oncology On The Go ·

2026/01/12

In a conversation with CancerNetwork®, Nathan Goodyear, MD, provided an overview of how to implement integrative modalities that may effectively supplement standard-of-care oncologic therapies. Beyond the use of intravenous vitamin C and other flagship strategies at his institution, Goodyear addressed potential misconceptions and biases surrounding integrative oncology and discussed how to re-engage patients back into evidence-based care.Goodyear, an integrative oncologist at the Williams Cancer

en-us

15:39

S1 Ep195: Advancing Research and Combatting...

Oncology On The Go ·

2026/01/05

In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioeconomic drivers of disparate patient outcomes, and translational research focusing on factors like the

en-us

28:02

S1 Ep194: What’s New in Hematology/Oncology?...

Oncology On The Go ·

2025/12/29

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes.Adams and Banerjee

en-us

47:48

S1 Ep193: Distress Screening: Making the Fifth Vital...

Oncology On The Go ·

2025/12/22

This episode of the collaborative podcast between Oncology on the Go and the American Psychosocial Oncology Society (APOS), hosted by Daniel C. McFarland, DO, features Michelle B. Riba, MD, and focuses on integrating psychosocial care into oncology for clinicians.The discussion emphasizes that psychosocial issues profoundly impact both quality of life and cancer-related outcomes, making their assessment an integral part of care, not merely ancillary. The distress thermometer was developed by the

en-us

10:10

S1 Ep192: ASH 2025: Key Discussions in Multiple...

Oncology On The Go ·

2025/12/15

At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations.First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study

en-us

53:55

S1 Ep191: Why Sexual and Gender Minority Care is an...

Oncology On The Go ·

2025/12/08

In the most recent ONCOLOGY On the Go hosted in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, spoke with Charles S. Kamen, PhD, MPH, about health equity for sexual and gender minority groups in oncology. Sexual and gender minority groups, who constitute approximately 9.3% of the US population, experience significant and preventable disparities across all stages of the cancer care continuum, according to Kamen.1 He detailed how these inequities are largely

en-us

13:07

S1 Ep190: Evolutions Across NSCLC, Multiple Myeloma,...

Oncology On The Go ·

2025/12/01

As part of a visit to Georgia Cancer Center in Augusta, Georgia, CancerNetwork spoke with a variety of experts and faculty members regarding ongoing research and future initiatives dedicated to improving outcomes across different patient populations. These conversations touched upon potential developments in diseases including non–small cell lung cancer (NSCLC), multiple myeloma, and acute myeloid leukemia (AML).First, Girindra Raval, MD, an associate professor in the Department of Medicine:

en-us

51:46

S1 Ep189: Decision-Making Capacity: The Ethical Core...

Oncology On The Go ·

2025/11/24

In a collaborative podcast with the American Psychosocial Oncology Society hosted by Daniel C. McFarland, DO, guests Louis P. Voigt, MD, and Yesne Alici, MD, discussed the ethical and clinical complexities of assessing decision-making capacity (DMC) in oncology, emphasizing its role as the ethical core of person-centered care. The discussion began by dissecting modern medicine’s need for formal DMC assessment. Voigt framed DMC as a fundamental issue of patient rights and respect, asserting that

en-us

12:42

S1 Ep188: How Can Chlorotoxin-Directed CAR T-Cell...

Oncology On The Go ·

2025/11/17

In a conversation with CancerNetwork®, Michael Barish, PhD, spoke about an investigational CAR T-cell therapy that he and colleagues are developing as a treatment for patients with glioblastoma. He and his team designed the agent to harness chlorotoxin, an amino acid peptide toxin component of scorpion venom, as a vehicle for intratumoral delivery of therapy for this patient population.Barish, a chair in the Department of Neurosciences/Developmental & Stem Cell Biology at City of Hope,

en-us

26:03

S1 Ep187: How Supportive Care Methods Can Improve...

Oncology On The Go ·

2025/11/10

The latest episode of Oncology On the Go focused on survivorship and supportive care. Stemming from conversations with leading clinicians in the field, the compilation highlights gaps and educational insights into multiple areas. Covering topics like nutrition, oncodermatology, body image, sexual health, and mortality, these conversations explored how to truly optimize multidisciplinary cancer care. Declan Walsh, MD, chair of the Department of Supportive Oncology at Atrium Health Levine Cancer

en-us

29:03

S1 Ep186: How Will Gastrointestinal Cancer Standards...

Oncology On The Go ·

2025/11/03

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT

en-us

11:31

S1 Ep185: What Were the Key Presentations at ESMO...

Oncology On The Go ·

2025/10/27

As part of the European Society for Medical Oncology (ESMO) Congress 2025, CancerNetwork® spoke with a variety of experts about key takeaways from different late-breaking abstracts, oral presentations, and other sessions focused on potential advancements across cancer care. Presenting investigators highlighted updated results from clinical trials evaluating novel therapeutic strategies across different cancer populations, including breast cancer and lung cancer. Phase 3 VIKTORIA-1 Trial Sara A

en-us

13:12

S1 Ep184: Leveraging Biology to Advance the Small...

Oncology On The Go ·

2025/10/20

In a discussion with CancerNetwork®, Anne Chiang, MD, PhD, spoke about the current treatment landscape for those with small cell lung cancer (SCLC) as well as next steps for elevating the quality of care among patients. She began by outlining the evolution of therapeutic standards in the field, with atezolizumab (Tecentriq)- and durvalumab (Imfinzi)-based regimens emerging as key frontline strategies and lurbinectedin (Zepzelca) and tarlatamab-dlle (Imdelltra) demonstrating utility as second-line

en-us

17:57

S1 Ep183: Charting the Evolution of TKIs and Finding...

Oncology On The Go ·

2025/10/13

In a conversation with CancerNetwork®, Jorge Cortes, MD, explored the evolution of the chronic myeloid leukemia (CML) landscape. Specifically, he highlighted how the development of ibrutinib (Gleevec) paved the way for other tyrosine kinase inhibitors (TKIs) and described where research must go next in terms of implementing fixed-duration therapy and targeting genetic abnormalities.Cortes, the director, and Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer at the Georgia Cancer Center,

en-us

26:30

S1 Ep182: Optimizing Care for TILs, Cellular Therapy...

Oncology On The Go ·

2025/10/06

In a special co-branded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at

en-us

17:02

S1 Ep181: Gemcitabine Intravesical System Offers...

Oncology On The Go ·

2025/09/29

In a conversation with CancerNetwork® following the FDA approval of the gemcitabine intravesical system (Inlexzo; formerly TAR-200) for patients with high-risk, Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC), Gary Steinberg, MD, discussed how this regulatory decision may impact the treatment paradigm.Steinberg, a professor in the Department of Urology at Rush University, highlighted an unmet need for those with BCG-unresponsive, high-grade NMIBC. With a

en-us

226 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter